Disclosed positions

Estimated from their latest filings — positions may have changed since

$3.54M

combined est. value

Stock	Shares	Price	Value	Weight	As of
TVTXTravere Therapeutics, Inc.	56,250	$58.36	$3.28M	93%	2026-05-19
VIRVir Biotechnology, Inc.	16,000	$10.43	$166.9K	5%	2026-06-09
ADCTADC Therapeutics SA	72,400	$1.28	$92.7K	3%	2026-06-03

TVTX

Travere Therapeutics, Inc.

$3.28M

56,250 sh

VIR

Vir Biotechnology, Inc.

$166.9K

16,000 sh

ADCT

ADC Therapeutics SA

$92.7K

72,400 sh

All filings on record

Every Form 4 transaction we track for this filer

all 10buys 0sells 2

Stock	Transaction	Date	~6mo later
VIRVir Biotechnology, Inc.	Grant — · 8,000 sh	2026-06-09	—
VIRVir Biotechnology, Inc.	Grant — · 8,000 sh	2026-06-09	—
ADCTADC Therapeutics SA	Tax $38.8K · 12,600 sh	2026-06-03	—
ADCTADC Therapeutics SA	Grant — · 45,000 sh	2026-06-01	—
TVTXTravere Therapeutics, Inc.	Grant — · 4,000 sh	2026-05-19	—
TVTXTravere Therapeutics, Inc.	Sell $141.3K · 3,250 sh	2026-05-15	—
TVTXTravere Therapeutics, Inc.	Sell $630.6K · 18,000 sh	2025-10-31	—
TVTXTravere Therapeutics, Inc.	Exercise $174.4K · 10,000 sh	2025-10-31	—
TVTXTravere Therapeutics, Inc.	Exercise $130.6K · 8,000 sh	2025-10-31	—
ADCTADC Therapeutics SA	Grant — · 40,000 sh	2025-06-03	—

VIRGrant

2026-06-09 · Vir Biotechnology, Inc.

8,000

—

VIRGrant

2026-06-09 · Vir Biotechnology, Inc.

8,000

—

ADCTTax

2026-06-03 · ADC Therapeutics SA

$38.8K

—

ADCTGrant

2026-06-01 · ADC Therapeutics SA

45,000

—

TVTXGrant

2026-05-19 · Travere Therapeutics, Inc.

4,000

—

TVTXSell

2026-05-15 · Travere Therapeutics, Inc.

$141.3K

—

TVTXSell

2025-10-31 · Travere Therapeutics, Inc.

$630.6K

—

TVTXExercise

2025-10-31 · Travere Therapeutics, Inc.

$174.4K

—

TVTXExercise

2025-10-31 · Travere Therapeutics, Inc.

$130.6K

—

ADCTGrant

2025-06-03 · ADC Therapeutics SA

40,000

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.